■ 人见人爱的生理盐水/PBS ■ 忍辱负重的有机溶剂们 1、DMSO 萌 Cece:只要溶解度允许,可以降低 DMSO 含量,建议取少量尝试,因为水溶性如果很差的话,可能会有析出。尽量使用 Tween-80 , 动物耐受性更好些;PEG300 的比例可上调, 90% PEG300 用于裸鼠腹腔给药也是有报道的;另外,PEG400 可以替代,也有用 PEG600 的,但不是很建议,因为熔点接近常温。整体来说,PEG300 不管从耐受性,还是粘稠度上来说,都是最佳选择。 动物实验溶剂给药比例[7] ■ 常见的其它助溶剂 CMC-Na、MC 是常见的动物给药助溶剂,具有调节粘度、稳定乳液的作用。CMC-Na、MC 按照比例给药,对动物基本没有毒性。CMC-Na 溶解药物一般会形成均匀的混悬液,可用于腹腔和灌胃。需要注意的是,CMC-Na 混悬液需现用现配,不建议长期储存。 SBE-β-CD 是增加疏水性药物溶解度的理想媒介,已在 FDA 批准的多种注射剂和众多临床候选药物中使用。SBE-β-CD 溶液可以用于多种给药方式,例如腹腔、灌胃、静脉等。 好啦,关于动物溶剂萌 Cece 就介绍这么多了。当然还有很多其他的助溶剂,比如 Polyethylene glycol 12-hydroxystearate、玉米油等等,至于您的实验到底适合哪一种溶剂,比例该设定为多少,萌 Cece 建议多查查相关文献,参考与您实验模型相似的文献。最后,祝愿大家没有溶解不了的药物,没有不成功的实验!
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务 参考文献 下滑查看更多 ↓ 1. Peng Jiang, Xinli Hu, Rui-Ping Xiao, et al. Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53. Mol Cell. 2021 Feb 4;81(3):629-637.e5. 2. Wangyue Jia, Jian Wu, Qiong Wu, et al. Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis. Cell Death Dis. 2021 Mar 26;12(4):327. 3. Ling He, Kun Xu, Zhaoqun, et al. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma. Aging (Albany NY). 2020 Mar 12;12(5):4547-4557. 4. Claus Brandt, Jens C Brüning, et al. Food Perception Primes Hepatic ER Homeostasis via Melanocortin-Dependent Control of mTOR Activation. Cell. 2018 Nov 15;175(5):1321-1335.e20. 5. Jatinder Kaur Mukker, Jane Alcorn, et al. Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats. Br J Nutr. 2015 Mar 14;113(5):749-57. 6. Alex B Burgin, Mark E Gurney, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010 Jan;28(1):63-70. 7. Ping Li, Luwei Zhao, et al. Developing early formulations: practice and perspective. Int J Pharm. 2007 Aug 16;341(1-2):1-19. 8. Md Ibrahim H Mondal, et al. Toxicity study of food-grade carboxymethyl cellulose synthesized from maize husk in Swiss albino mice. Int J Biol Macromol. 2016 Nov;92:965-971. 9. Qiuyang Zheng, Xin Wang, et al. Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer's brains is mediated by USP25. Sci Adv. 2021 Jan 1;7(1):eabe1340. 10. Can Tu, Xiao-He Xiao,1, Jia-Bo Wang, et al. Inflammatory stress potentiates emodin-induced liver injury in rats. Front Pharmacol. 2015 Oct 23;6:233. 11. Valentino J Stella, et al. Sulfobutylether-β-cyclodextrin. Int J Pharm. 2020 Jun 15;583:119396. 12. Z Alexander Cao, et al. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer Ther. 2006 Jul;5(7):1693-701. 13. R. P. Swain, et al. Effect of Solutol HS 15 in Solid Dispersions of Pioglitazone Hydrochloride: in vitro and in vivoEvaluation. Indian J Pharm Sci 2019;81(2):317-325. 14. Motohiro Nonaka, Michiko N. Fukuda, et al. Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours. Br J Cancer. 2020 Nov;123(11):1633-1643. 15. William R Schwan, et al. Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92. Antibiotics (Basel). 2015 Dec;4(4):617-626. 16. C A Castro, M R Landauer, et al. Behavioral effects of vehicles: DMSO, ethanol, Tween-20, Tween-80, and emulphor-620. Pharmacol Biochem Behav. 1995 Apr;50(4):521-6. 17. Ellen Weisberg, James D. Griffin, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20. |
|